SCHEMBL6489502

SCHEMBL6489502

O=C(NCc1ccc(Cl)cc1)c1cnc2cc(I)sc2c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.48
EGLN1 Q9GZT9 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2C9 P11712 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLA1 P09884 2/20 0.43
LMNA P02545 2/20 0.43
NR3C1 P04150 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CYP3A4 P08684 1/20 0.42
POLB P06746 1/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
CYP1A1 P04798 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6706694 0.82 SMN1; SMN2 (0.48) MAOBEGLN1SMN1; SMN2HPGDCYP1A2
SCHEMBL6480113 0.81 EGLN1 (0.49) MAOBEGLN1SMN1; SMN2HPGDCYP1A2
SCHEMBL6198072 0.79 EGLN1 (0.47) MAOBEGLN1SMN1; SMN2HPGDCYP1A2
SCHEMBL6196111 0.79 EGLN1 (0.47) EGLN1SMN1; SMN2HPGDCYP1A2CYP2C19
SCHEMBL6198849 0.78 EGLN1 (0.51) MAOBEGLN1SMN1; SMN2HPGDCYP1A2
SCHEMBL6199742 0.78 EGLN1 (0.51) EGLN1SMN1; SMN2HPGDCYP1A2CYP2C19
SCHEMBL6201550 0.77 NR3C1 (0.51) MAOBEGLN1SMN1; SMN2HPGDCYP1A2
SCHEMBL6198157 0.76 EGLN1 (0.55) EGLN1SMN1; SMN2HPGDCYP1A2CYP2C19
SCHEMBL6194761 0.76 POLA1 (0.54) MAOBEGLN1SMN1; SMN2HPGDCYP1A2
SCHEMBL6200824 0.75 EGLN1 (0.48) MAOBEGLN1SMN1; SMN2HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861438-B2 Antiviral agents PFIZER (US) 2005-03-01 US disclosed
EP-1467999-A1 OXOTHIENO[3,2-B]PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-20 EP disclosed
US-20040138449-A1 Antiviral agents PHARMACIA & UPJOHN COMPANY 2004-07-15 US disclosed
WO-2003059912-A1 OXOTHIENO (3, 2-B) PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138449-A1 Antiviral agents IRF3, IFNAR1, EIF2AK2 MAOB 4441/4885EGLN1 3432/4885SMN1; SMN2 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.